AstraZeneca, a multinational, pharmaceutical and biopharmaceutical company studied to create a drug that would help the patients fighting with lung cancer. The drug is for the patients in which the lung cancer had not spread. The company aimed at changing the way, for the treatment of the disease and to increase the screening of disease.
The results of the study named Pacific were published and it stated that the immune system of a person can attack the tumor to kill it before it spreads.
The Imfinzi medicine has helped to lower the death risk of persons by one-third, who were being treated with Chemotherapy alone previously. These were the people in a cancer stage of third or fourth.
Pascal Soriot executive at the company puts the success on the center of his successful appeal to shareholders, which was to reject a takeover bid from Pharm Giant Pfizer four years ago. Companies like Merck and Bristol-Myers Squibb had already developed successful immunotherapy treatments and rivals or AstraZeneca got an advantage on the treatment before this company could.
Head of Oncology business unit at AstraZeneca said that it is for the first time they had seen earlier benefits of a treatment, in lowering cancer mortalities. Moving earlier with immuno-oncology agents could help in cancer cure one day.
Imfinzi was already been used in the U.S. Recently European Commission also approved the treatment. The major difficulty was in the diagnosis of disease before it reaches stage four. For this, Mr. Fredrickson stated Imfinzi post-chemo radiotherapy as a standard of care.
The crux of the matter is that quicker we identify cancer, the sooner we can overcome it.